Overview

STATEMENT OF NEED

Prostate cancer is the most common tumor type affecting men in the United States, with an estimated 174,650 new cases reported each year. Typically, androgen deprivation therapy is administered for progressive disease. However, castration resistance or unresponsiveness to androgen deprivation therapy or to antiandrogens frequently develops over time. The transition from castration-sensitive to castration-resistant disease has yet to be understood and represents a significant unmet need. Nonmetastatic castration-resistant prostate cancer (CRPC) is a highly heterogeneous disease process with a dearth of effective treatment options. Metastatic CRPC is the primary cause of prostate-related mortality, accounting for an estimated 31,620 deaths annually. Median overall survival remains less than 2 years.

TARGET AUDIENCE

Oncologists, urologists, nurse practitioners, pharmacists, nurses, and other military health care professionals involved in the treatment of patients with CRPC.

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

• Evaluate emerging efficacy and safety data on novel therapies for nonmetastatic and metastatic CRPC
• Apply strategies to monitor and manage adverse events associated with novel therapies for nonmetastatic and metastatic CRPC
• Assess the role of imaging studies and prostate-specific antigen testing in evaluating treatment response

Note: The learning objectives listed above apply to pharmacists, nurse practitioners, and registered nurses in addition to physicians.

FACULTY

Ulka N. Vaishampayan, MD (Chairperson)
Professor of Medicine
University of Michigan

Leonard G. Gomella, MD, FACS
Bernard W. Godwin, Jr. Professor of Prostate Cancer
Thomas Jefferson University

Julie N. Graff, MD
Associate Professor of Medicine
VA Portland Health Care System

Matthew Rettig, MD
Professor of Medicine and Urology
University of California, Los Angeles

REGISTRATION

There is no fee to participate in or claim CME/CNE/CPE credit for this activity.

Please note that i3 Health does not accept responsibility for travel, accommodation, or any other costs incurred by registrants in the rare event that this activity should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation.

Co-Provided by

Physicians

i3 Health is accredited by the American Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

i3 Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants

American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities approved for AMA PRA Category 1 Credit™ from organizations accredited by ACCME. Physician assistants may receive a maximum of 1.0 hour of Category 1 credit for completing this program.

Nurse Practitioners

The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

Continuing Nursing Education

i3 Health is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

A maximum of 1.0 contact hour may be earned by learners who successfully complete this continuing nursing education activity. This activity has been approved for 0.9 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

Provider approved by the California Board of Registered Nursing, Provider Number 15824, for 1.0 contact hour.

Continuing Pharmacy Education

USF Health is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This knowledge-based program has been approved for 1.0 contact hour (1.0 CEU). Universal program number is as follows: 0230-0000-22-007-L01-P.

ONCC RECERTIFICATION

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.

ONCC review is only for designating content to be used for recertification points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the CNE provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.

OCN^®, CPHON^®, CBCN^®, AOCNP^®, AOCNS^®, and BMTCN^® renewal candidates may apply 1 ILNA point toward:

• Coordination of Care
• Diagnosis and Staging
• Health Promotion/Screening and Early Detection
• Cancer Continuum
• Oncology Nursing Practice
• Scientific Basis for Practice
• Survivorship
• Symptom Management
• Treatment

Please note that some of the course content applies to multiple content areas. The numerical value above indicates the maximum amount of points that can be claimed in each domain. The total amount of ILNA points claimed may not exceed the total amount of CNE awarded from this course.

DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH COMMERCIAL INTERESTS

i3 Health and USF Health endorse the standards of the ACCME, ACPE, and ANCC that require everyone in a position to control the content of a CME/CNE/CPE activity to disclose all financial relationships with commercial interests that are related to the content of the CME/CNE/CPE activity. CME/CNE/CPE activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

A conflict of interest is created when an individual has an opportunity to affect CME/CNE/CPE content about products or services of a commercial interest with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.

i3 Health and USF Health will identify, review, and mitigate all conflicts of interest that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health and USF Health do not endorse any products or services.

Relevant financial relationships exist between the following individuals and commercial interests:

Ulka N. Vaishampayan, MD, discloses that she has served as a consultant for Bayer and on the speakers' bureau for Bayer, Pfizer, and Sanofi. She has also received research support from Novartis and Pfizer.

Leonard G. Gomella, MD, FACS, discloses that he has served on the advisory board for Astellas, Bayer, Clovis, Janssen, and Merck. He has also served as a consultant for Strand Diagnostics.

Julie N. Graff, MD, discloses that she has received research support from Astellas, Janssen, Merck, and Sanofi.

Matthew Rettig, MD, discloses that he has served on the advisory board for Constellation Pharmaceuticals and on the speakers' bureau or as a consultant for Bayer and Johnson & Johnson. He has received research support from Astellas, Medivation, Merck, and Novartis.

Judd W. Moul, MD, discloses that he has served on the advisory board for Pfizer, on the speakers’ bureau for ExosomeDx, Genomic Health, Janssen, and Sanofi, and as a consultant for Theralogix. He has also received grants/research support from Astellas and Pfizer.

i3 Health has mitigated all relevant financial relationships.

The i3 Health planners, reviewers, and managers have nothing to disclose.

USF Health OCPD staff members have no relevant financial relationships to disclose.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, participants must attend the scheduled activity and submit a completed evaluation at the end of the activity.

UNAPPROVED USE DISCLOSURE

i3 Health and USF Health require CME/CNE/CPE faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.

This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

DISCLAIMER

The information provided at this CME/CNE/CPE activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

COMMERCIAL SUPPORT

This activity is supported by independent educational grants from Sanofi and Clovis Oncology.

Aggregate participant data will be shared with commercial supporters of this activity.

AMERICANS WITH DISABILITIES ACT

Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc.). Please contact i3 Health prior to the live event at 973-928-8085 or This email address is being protected from spambots. You need JavaScript enabled to view it..

CONTACT INFORMATION

Technical queries or questions regarding activity credit should be directed to i3 Health at This email address is being protected from spambots. You need JavaScript enabled to view it.